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Few children with drug-resistant (DR) tuberculosis (TB) are identiﬁed, diagnosed, and given an appropriate
treatment. The few studies that have described this vulnerable population have used inconsistent deﬁnitions.
The World Health Organization (WHO) deﬁnitions used for adults with DR-TB and for children with
drug-susceptible TB are not always appropriate for children with DR-TB. The Sentinel Project on Pediatric
Drug-Resistant Tuberculosis was formed in 2011 as a network of experts and stakeholders in childhood DR-
TB. An early priority was to establish standardized deﬁnitions for key parameters in order to facilitate study
comparisons and the development of an evidence base to guide future clinical management. This consensus
statement proposes standardized deﬁnitions to be used in research. In particular, it suggests consistent
terminology, as well as deﬁnitions for measures of exposure, drug resistance testing, previous episodes and
treatment, certainty of diagnosis, site and severity of disease, adverse events, and treatment outcome.
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The World Health Organization (WHO) estimated that
650 000 cases of multidrug-resistant (MDR) tuberculosis
(TB) occurred globally in 2010 [1]. MDR-TB is caused
by Mycobacterium tuberculosis, which is resistant to the
2 most effective ﬁrst-line medications: rifampin and iso-
niazid [2]. In high-burden settings, pediatric TB com-
prises 15%–20% of the total disease burden [3-4]; this
equates to a global estimate of up to 100 000 children
with MDR-TB. Children traditionally have been neglect-
ed by both healthcare systems and research [5]. This is
especially true for children with drug-resistant (DR)-TB,
with fewer than 500 children with MDR-TB described
in the medical literature to date [6]. With the imminent
roll-out of newer molecular diagnostic tests [7-8], more
children will be identiﬁed both as conﬁrmed DR-TB
cases, as well as presumed TB cases that have been in
contact with a DR-TB source case. The limited number
of studies to date and challenges evident in data collec-
tion highlight the need for improved coordination and
standardization of data to ensure the development of an
evidence base to inform the management of these
children.
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Tuberculosis was formed in 2011 as a virtual community
of experts and stakeholders who share the goal of prevent-
ing child deaths from DR-TB [9]. More than 200 research-
ers, healthcare providers, and advocates from over 40
countries are now collaborating in this global network.
Task forces take on speciﬁc projects that seek to develop,
deploy, and disseminate evidence-based strategies for im-
proving the detection and treatment of children with
DR-TB. One immediate priority for this network was to es-
tablish standardized deﬁnitions for key variables, terms,
and outcomes, to facilitate study comparisons and research
collaborations. The task force that developed this consen-
sus statement has particular experience in carrying out re-
search related to DR-TB in children. The proposed
deﬁnitions were revised through meetings, conference calls,
and written feedback to achieve clarity and consensus.
The current programmatic WHO deﬁnitions used to
describe adults with DR-TB and children with drug-
susceptible (DS) TB were considered to be inadequate for
research studies of children with DR-TB. More rigorous
deﬁnitions were required for use in research that records
the epidemiology of exposure, infection and disease, as
well as research into diagnosis, treatment, prevention, and
outcome. Deﬁnitions were intended to be relevant for both
prospective studies, in which comprehensive data can be
collected, and for retrospective studies. The distinction
between deﬁnitions used in clinical management, pro-
grammatic reporting, and research studies is complex;
many research studies document clinical management or
report programmatic data. Although we hope that the deﬁ-
nitions suggested will strengthen programmatic reporting,
this article proposes standardized consensus deﬁnitions in-
tended for use in the research setting. These deﬁnitions are
not intended for use by clinicians who make decisions re-
garding the management of children with DR-TB infection
and disease.
Terminology and Measures of Exposure
To facilitate comparisons between different studies it is
vital that key terms be standardized. Table 1 provides a
summary of the suggested consensus deﬁnitions regarding
epidemiologic terms, disease classiﬁcation, type of treat-
ment, and categories of drug resistance.
Exposure is a continuum, with no documented exposure
at one extreme and extensive exposure at the other.
Although any exposure to a DR-TB source case could po-
tentially result in a child becoming infected, in reality this
exposure must reach a signiﬁcant threshold for the child to
be deemed a contact. This necessitates the use of a binary
deﬁnition. The issue is complex and incorporates elements
of the infectiousness of the source case, the proximity and
intensity of interaction between source case and contact,
the daily duration of exposure, the length of exposure over
time, as well as environmental factors such as air exchange
[10-11].Different deﬁnitions will provide different degrees
of sensitivity and speciﬁcity, and it is important that deﬁni-
tions are consistent and well described. Recent interactions
are more likely to result in disease in the child compared
with interactions that took place more than 1 year ago
[12-15].
This task force came to the consensus that a “DR-TB
contact” should be deﬁned as a child exposed to an infec-
tious DR-TB source case who, in the last 12 months, had
either slept in the same household or had daily interaction
with the child [16]. We propose that, if possible, a set of
10 questions be answered to provide an exposure “score”
(see Table 1), where the sum of binary responses valued at
0 (no) or 1 (yes) result in a contact score ranging from 0 to
10. This concept comprises 4 unique aspects of TB expo-
sure, which provide a more precise and comprehensive de-
scription of the likely infection risk and correlates well
with tests of M tuberculosis infection [11].
In the same way that exposure is a gradient, so too is the
spectrum from exposure through infection to disease [17].
Despite this continuum, it is necessary to assign children
into distinct categories for research studies. The terminolo-
gy used in the literature for children who demonstrate im-
munological evidence of infection with M tuberculosis, in
the absence of clinical symptoms, is confusing. Latent TB
infection, latent TB, M tuberculosis infection, and TB
infection have all been used. The word “tuberculosis”
implies a disease state, and therefore we thought that TB
infection should not be used for a well child. For children
who have been recently infected by M tuberculosis, the use
of the word latency is incongruous because it implies an
established immunological equilibrium, which may not
have been achieved. We suggest that a child with a positive
immunological test (eg, tuberculin skin test or interferon-γ
release assay) should be classiﬁed as having “M tuberculo-
sis infection” to cover both recent and latent infection.
This is consistent with other consensus deﬁnitions [18]. In
order for a child to be classiﬁed as having “DR M tubercu-
losis infection,” the child must have a positive immunolog-
ical test result as well as being a DR-TB contact. The
terminology used for children with clinical, radiological,
or microbiological pathology is similarly inconsistent
across the published literature. “Active disease” is a term
used widely to denote an ill child, but “inactive disease”
was not felt to be a useful concept. For consistency, we
suggest that the term “TB disease” be used.
Consensus Statement on Research Deﬁnitions 101Table 1. Proposed Terminology for Drug-Resistant Tuberculosis in Children and the Assessment of Drug-Resistant Tuberculosis Exposure
Recommended Term Definitions
Epidemiological terms DR-TB index case The first identified, confirmed DR-TB case in a social group (eg, a household) during an investigation or outbreak (which may be the child)
DR-TB source case An infectious (sputum-smear microscopy or culture positive) DR-TB case who could have infected the contact
DR-TB contact A child exposed to an infectious DR-TB source case who, in the last 12 months, had either slept in the same household or had daily
interaction with the child [16]
DR-TB exposure score Ten points to be used for exposure score [11]
￿ Is the source case the child’s mother?
￿ Is the source case the child’s primary caregiver?
￿ Does the source case sleep in the same bed as the child?
￿ Does the source case sleep in the same room as the child?
￿ Does the source case live in the same household as the child?
a
￿ Does the source case see the child every day?
a
￿ Is the source case coughing?
￿ Does the source case have pulmonary TB?
￿ Is the source case sputum-smear microscopy positive?
￿ Is there more than one source case in the child’s household?
Infection and disease M tuberculosis
infection
A positive immunological test of infection (eg, tuberculin skin test or interferon-γ release assay), in the absence of symptoms and physical
signs (both acute and chronic) [18]
DR M tuberculosis
infection
A positive immunological test of infection, in the absence of symptoms and physical signs (both acute and chronic), but in combination with
being a DR-TB contact
TB disease Clinical, radiological, or microbiological pathology
DR-TB disease Clinical, radiological, or microbiological pathology, in combination with diagnosis of confirmed, probable, or possible DR-TB disease (see
Table 2)
Type of treatment DR-TB treatment The treatment of DR-TB disease
DR-TB preventive
therapy
Includes DR-TB pre-exposure (primary) prophylaxis, DR-TB post-exposure prophylaxis (including window prophylaxis), DR-TB secondary
prophylaxis, and treatment of DR M tuberculosis infection
Drug resistance
categories
Monoresistant Resistance to a single TB drug
Polyresistant Resistance to 2 or more TB drugs other than both rifampin and isoniazid
MDR Resistant to at least both rifampin and isoniazid
Pre-extensively DR MDR-TB with resistance to either a fluoroquinolone, or at least 1 of 3 injectable second-line TB drugs,
b but not both
Extensively DR MDR-TB with resistance to both a fluoroquinolone and at least 1 of 3 injectable second-line TB drugs
b
Primary resistance DR-TB that results from transmission of a DR M tuberculosis strain. This could be any of the after clinical situations in a child newly
diagnosed with confirmed or probable DR-TB:
(a) never treated: a child without previous TB treatment who has not yet received any TB treatment; or
(b) previously treated: a child who was previously treated with first-line drugs who was either cured or completed that treatment regimen; or
(c) currently receiving treatment: a child who is receiving first-line drugs for presumed DS-TB disease.
Acquired resistance A child previously diagnosed with confirmed DS-TB disease who developed DR-TB disease (or resistance to additional drugs) during TB
treatment.
Abbreviations: DR, drug-resistant; DS, drug-susceptible; MDR, multidrug-resistant; M tuberculosis, Mycobacterium tuberculosis; TB, tuberculosis.
aEither of these 2 components will classify the child as being a DR-TB contact if occurring in the preceding 12 months.
bAmikacin, kanamycin, capreomycin [2].
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disease include “curative treatment,”“ disease treatment,”
“anti-TB treatment,” and “TB treatment.” To avoid ambi-
guity, we suggest using the term “TB treatment.” In the ex-
isting literature, there is also inconsistency surrounding the
terminology used to describe other forms of chemothera-
py. Pre-exposure prophylaxis refers to treatment given to a
child without known exposure to an infectious TB case.
Postexposure (including window) prophylaxis refers to
treatment given to a child after documented TB exposure.
Treatment of latent TB infection refers to drugs given after
a positive immunological test result indicating previous or
current M tuberculosis infection. Posttreatment prophy-
laxis refers to treatment given to a child after a course of
TB treatment. For consistency, we suggest the use of the
summative term “TB preventive therapy” to cover all of
these circumstances.
Deﬁnitions of Drug Resistance and Testing Methodology
Although drug resistance is generally divided into the dis-
crete categories of mono-, poly-, MDR-TB or extensively
DR-TB [2] (see Table 1), it is more useful to view drug re-
sistance as a continuum. For research into pediatric
DR-TB, it is important to describe the precise drug-
susceptibility test (DST) pattern. It is also important to
record the DST pattern of the likely source case(s), rather
than their DST category, when the child has been diag-
nosed presumptively.
Due to the wide variety of testing methodologies avail-
able to determine drug resistance, at a minimum, research-
ers should clearly state the laboratory techniques used in
determining drug resistance. It should be documented to
which drugs DST was performed and which techniques
were used for each of the drugs. If DST is determined by
phenotypic testing, the Clinical and Laboratory Standards
Institute standards should be used [19]. It is anticipated
that more DST will be carried out using genotypic
methods in the future. More than 10 genotypic tests exist
using nucleic acid ampliﬁcation to determine drug resis-
tance [20].Some assays only determine whether the organ-
ism belongs to the M tuberculosis complex and whether
mutations in the rpoB gene are present (associated with ri-
fampin resistance in >95% cases). The Xpert MTB/RIF
assay (Cepheid, Sunnyvale, CA) is one such test, which is
currently being rolled out widely [7].If this test is used and
the rpoB mutation result is positive, the sample should be
recorded as having resistance to rifampin, because this test
cannot conﬁrm or rule out resistance to isoniazid. The fre-
quency of rifampin-monoresistant strains is increasing in
some settings [21], and samples found to be rifampin-
resistant should therefore not be assumed to also be resis-
tant to isoniazid. Conversely, isoniazid-monoresistant TB
is common in many regions; if a sample is found not to
have an rpoB gene mutation, it should not be assumed to
be fully DS. Consequently, it is important to follow up
results from nucleic acid ampliﬁcation tests that only
detect rifampin resistance with additional testing for isoni-
azid resistance.
The genotypic testing of resistance to isoniazid usually
involves testing for mutations in the inhA promoter region
and the katG gene [22]. A molecular line probe assay (eg,
GenoType MTBDRplus; Hain Lifescience, Nehren,
Germany) is frequently used for this purpose. As well as
recording the presence of genotypic resistance to isoniazid,
it is desirable to also record the mutation conferring resis-
tance, because this has clinical and epidemiological signiﬁ-
cance [23]. Other molecular tests are under development
and in the future, genotypic testing to the second-line
drugs is likely to become more widespread, because drug
resistance to these agents is associated with known gene
mutations [24].
Certainty of Diagnosis of Disease
When treating children for DR-TB disease, the decision is
binary – the child is treated or not. For the clinician, this
diagnosis is either conﬁrmed or presumed. Either of these
diagnoses may be sufﬁcient for clinical management and
for recording and reporting purposes. For research pur-
poses, however, it is important to document the degree of
certainty for both the diagnosis of TB and the diagnosis of
drug resistance (see Table 2). For the diagnosis of TB
disease in children, the WHO ﬁrst proposed categories of
suspect, probable, and conﬁrmed TB for reporting and for
research [25]. This classiﬁcation has recently been reﬁned
by a National Institutes of Health expert panel, focusing
speciﬁcally on intrathoracic disease [18]. For extrathoracic
TB, a similar system should be adopted; one has been pro-
posed for TB meningitis [26]. As with the deﬁnitions
advised by Graham et al [18], at least 1 sign or symptom
of TB is required for the research deﬁnition of TB disease.
Children without clinical manifestations consistent with
TB disease will therefore not meet the strict research crite-
ria, even though in clinical practice a physician may initi-
ate treatment.
Ad e ﬁnition of “conﬁrmed DR-TB disease” requires
clinical evidence of TB disease together with the detection
of M tuberculosis from a specimen collected from the child
with resistance demonstrated. We strongly support all
specimens from children being submitted for culture and
DST. A deﬁnition of “probable DR-TB disease” should be
used when a diagnosis of probable TB disease has been
made and the child is a DR-TB contact. Cases should be
classiﬁed as “possible DR-TB disease” if a diagnosis of
probable TB disease has been made and either the child
Consensus Statement on Research Deﬁnitions 103fails adherent ﬁrst-line TB treatment or has been exposed
to a source case with risk factors for drug resistance (failed
therapy, death, or default with no known DST).
Previous Episodes and Treatment
A distinction should be made between a previous episode
of disease and any previous treatment given, because this
will have implications both for research aimed at improv-
ing clinical management of individual patients and for re-
search aimed at improving programmatic strategies.
Deﬁnitions have been previously proposed for classifying
patients who are newly diagnosed, previously treated with
ﬁrst-line drugs, and previously treated with second-line
drugs [2]. However, no deﬁnitions have been proposed for
a previous TB disease episode or for a previous DR-TB
disease episode. We propose deﬁnitions to classify both of
these types of disease episode (see Table 2). One recent
study used a 6-month symptom-free period after the com-
pletion of at least 1 month of previous treatment as a prag-
matic differentiator of disease episodes [27].
For a child newly diagnosed with conﬁrmed or probable
DR-TB disease, it is important to distinguish among
several clinical scenarios. The ﬁrst 3 scenarios are exam-
ples of transmitted or primary resistance, whereas the
fourth is an example of acquired resistance (Table 1):
(1) A child without previous TB treatment who has not yet
received any TB treatment (primary resistance in a
never treated child);
(2) A child who was previously treated with ﬁrst-line
drugs who was either cured or completed that treat-
ment regimen (primary resistance in a previously
treated child);
(3) A child who is currently receiving ﬁrst-line drugs for
presumed DS-TB disease (primary resistance in a child
currently receiving treatment); and
(4) A child previously diagnosed with conﬁrmed DS-TB
disease who developed DR-TB disease during treat-
ment with ﬁrst-line drugs.
Although clinically it is sensible to suspect the develop-
ment of resistance in a child if treatment has been poorly
adhered to or incorrectly prescribed or supplied, for this
conclusion to be reached in a research context, it is neces-
sary to have had an initial DS isolate. Most children with
DR-TB disease, however, have transmitted resistance [28].
To document treatment delay, a standard deﬁnition of
when the DR-TB episode began should be used to deter-
mine the interval from the assumed start of the disease
episode to the start of DR-TB treatment. Published studies
have deﬁned a DR-TB episode as beginning (in the event
that DR-TB was subsequently conﬁrmed) at either the
child’s initial documented presentation to the healthcare
system, when a specimen was obtained that eventually
conﬁrmed DR-TB, or alternatively, when the child com-
menced TB treatment for the current episode, based on
whichever was the ﬁrst documented event [27].
Site of Disease and Disease Severity
Site and severity of disease can have an impact on the
choice and duration of treatment as well as treatment
outcome. Disease severity, for example, has been shown to
correlate with bacterial yield in children and culture con-
version [27, 29-30]. TB programs usually report disease
site using ICD-10 codes [31], and this task force came to
the consensus that these codes should be used for report-
ing disease site in children with DR-TB. Deﬁning the
severity of disease in children is challenging and existing
approaches are limited. Radiological ﬁndings can be used
to describe the spectrum of intrathoracic disease and can
be an indicator of severity [32].A recently proposed classi-
ﬁcation system divides different types of both intra- and
extrathoracic childhood TB into severe and nonsevere
disease based on known host-pathogen interaction and
pathophysiology of disease [29]. Future studies need to
ensure the accuracy of this classiﬁcation system across pe-
diatric TB populations. Furthermore, this classiﬁcation
system should be evaluated prospectively in children with
DR-TB disease, because its correlation with treatment re-
sponse, disease progression, and outcome is still
unknown. Where possible, we propose that this classiﬁca-
tion should be used for research purposes.
Adverse Events
Second-line TB drugs are associated with increased risk of
adverse events [33]. For research, it is important to deter-
mine the type of adverse event, the severity, the relation-
ship to the medications being given, any action taken and
any associated risk factors [34]. The Division of Micro-
biology and Infectious Diseases within the US National
Institute of Allergy and Infectious Diseases has published
tables to allow the grading of adverse events [35]. These
tables are speciﬁc for children and we recommend their
use for research on pediatric DR-TB. However, a number
of adverse events that are frequently encountered in the
treatment of children with DR-TB disease and DR M tu-
berculosis infection are not adequately covered in this clas-
siﬁcation system [36]. These include thyroid dysfunction,
hearing loss, arthralgia, and arthritis. Proposed criteria for
grading these adverse events are included in Table 3.
It is important to note the action taken when an adverse
event occurs [37]. For each adverse event, we recommend
that data be collected documenting whether any action
was taken and, if so, what type. Where possible, other
factors that may be associated with the adverse event
should be recorded. These include comorbidities such as
104 Seddon et alTable 2. Classification According to Previous Disease Episodes, Diagnostic Certainty, and Description of Drug-Resistant Tuberculosis Disease in Children
Recommended Term Definition
Certainty of diagnosis of
TB disease [18]
Confirmed TB disease At least 1 of the signs and symptoms suggestive of TB disease
a and microbiological confirmation of M tuberculosis
Probable TB disease At least 1 of the signs and symptoms suggestive of TB disease
a and the CR is consistent with intrathoracic TB disease
b and
presence of 1 of the following: (a) a positive clinical response to TB treatment, (b) documented exposure to a source case with
TB disease, or (c) immunological evidence of TB infection
Possible TB disease At least 1 of the signs and symptoms suggestive of TB disease
a and either (a) a clinical response to TB treatment, documented
exposure to a source case with TB disease or immunological evidence of TB infection, or (b) CR consistent with intrathoracic
TB disease
b
Certainty of diagnosis of
DR-TB disease
Confirmed DR-TB disease At least 1 of the signs and symptoms suggestive of TB disease
a and detection of M tuberculosis from the child with
demonstration of genotypic or phenotypic resistance
Probable DR-TB disease DR-TB contact and diagnosis of probable TB disease
Possible DR-TB disease Diagnosis of probable TB disease together with either (a) contact of a source case with TB disease who has risk factors for drug
resistance
c or (b) failure of first-line TB treatment
Previous episodes and
treatment
Previous TB disease episode An episode of TB disease in which treatment was given for at least 1 month, after which there was a reported symptom-free
period of 6 months before the start of the current DR-TB disease episode
DR-TB disease episode If DR-TB disease is subsequently confirmed, a TB disease episode that began when the child is first documented to have
presented to the healthcare system, when the specimen was obtained that eventually confirmed DR-TB disease, or when the
child commenced any TB treatment, whichever is the first available documented event [27]
Previously treated with first-line
TB drugs
Treatment for 1 month or more with any drug in Drug Group 1 [2]
Previously treated with
second-line TB drugs
Treatment for 1 month or more with any drug in Drug Groups 2-5 [2]
Site of TB and disease
severity
ICD-10 code Code to be recorded [31]
Severe disease A clinical syndrome classified as uncontrolled,
d disseminated,
e or complicated
f [29]
Nonsevere disease A clinical syndrome classified as controlled (limited), non-disseminated, and uncomplicated [29]
Abbreviations: CR, chest radiograph; DR, drug-resistant; M tuberculosis, Mycobacterium tuberculosis; TB, tuberculosis; WHO, World Health Organization.
aPersistent cough, weight loss, or failure to thrive; persistent unexplained fever; persistent unexplained lethargy or reduced playfulness; or the presence of any of the following in the neonate: pneumonia, unexplained
hepatosplenomegaly, or sepsis-like illness [18].
bFor extrathoracic TB disease, alternative appropriate radiological imaging should be substituted.
cRisk factors for DR-TB include: treatment failure, death during TB treatment, treatment default or nonadherence, previous treatment, exposure to a known DR-TB case, as well as having resided in or traveled to an area
with high prevalence of DR-TB [2].
dDisease resulting in significant local or peripheral tissue damage and caseous necrosis.
eDisease resulting from hematogenous bacillary spread, such as miliary TB, meningitis, bone marrow disease, or renal, hepatic, or splenic TB granulomata.
fDisease resulting in infiltration or compression of adjacent bronchial, vascular, cardiac, nervous, or osseous tissue, resulting in functional impairment. Often involves severe sequelae, with the exceptions of peripheral lymph
node disease, pleural effusion without emphysema, and skin disease.
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5human immunodeﬁciency virus infection (HIV), diabetes,
and asthma, as well as the nutritional status and the type
and severity of TB disease.
Disease Outcome
Adult guidelines typically use microbiological parameters
to determine response to treatment. The outcome deﬁni-
tions currently recommended by WHO for adults with
DR-TB disease were ﬁrst proposed by an expert consensus
group for use in the analysis of retrospective data. Cure
was deﬁned as “ﬁve consecutive negative cultures from
samples collected at least 30 days apart in the ﬁnal 12
months of treatment” [2, 38]. For children with DS-TB
disease, cure has been deﬁned as a child who is “sputum
smear-negative in the last month of treatment and at least
one previous occasion” [39]. This task force reasoned that
neither of these deﬁnitions was appropriate for children
with DR-TB disease. Instead, we propose to deﬁne “cure”
as the completion of treatment, with attainment of clinical
(resolution of symptoms and physical signs), radiological
(improvement of imaging abnormalities), and microbio-
logical (conversion of cultures) criteria (Table 4).
Because only a relatively small proportion of children will
have a conﬁrmed diagnosis at the beginning of their treat-
ment [40-42], and because microbiological investigations
are frequently not repeated during follow-up, the majority
of children will not fulﬁll the deﬁnition for cure. We chose
to deﬁne “probable cure” as the presence of the same con-
stellation of features, but without the microbiological com-
ponent. The proposed deﬁnitions for treatment outcome are
d e s c r i b e di nd e t a i li nT a b l e4. One consideration in using
this approach relates to the natural history of TB: in some
patients, disease involutes without treatment [15]. However,
it is impossible to predict which children will respond in this
manner and if the research terminology is consistently
applied across settings to facilitate comparisons, this should
not undermine the value of such deﬁnitions.
Treatment response can be divided into clinical, radio-
logical, and microbiological responses. A key component
of clinical response is nutritional status, with poor status
being a risk for both the development of TB disease as well
as poor treatment outcome [43-46]. Nutritional variables
that require monitoring, at a minimum, include height and
weight. These parameters should be assessed at treatment
initiation and then monthly and should then be plotted on
standardized growth charts (see Table 4). We propose that
an improvement in nutritional status (ie, resolution of
failure to thrive) should be included among the criteria
used to deﬁne “probable cure.” Radiological improvement
encompasses partial or complete resolution of chest radio-
graphic features. However, it is important to consider that
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106 Seddon et alTable 4. Classification of Treatment Outcome in Children With Drug-Resistant Tuberculosis
Recommended Term Definition
Treatment
outcome
Cure Completion of prescribed treatment
a with attainment of clinical (resolution of symptoms and physical signs
b), radiological (improvement of imaging
abnormalities
c), and microbiological (conversion of cultures
d) criteria.
Probable cure Completion of prescribed treatment
a with attainment of clinical
b and radiological
c improvement
Treatment completed Completion of prescribed treatment
a
Default Treatment interruption for 2 months or more
Primary default Never started on DR-TB treatment
Death Death for any reason while on DR-TB treatment
Primary death Death before starting DR-TB treatment
Treatment failure Ongoing sputum culture positivity, or does not meet criteria for both clinical
b and radiological
c improvement, after more than 6 months of the child
receiving an appropriate DR-TB regimen (with adherence >80%) in the absence of IRIS
Abbreviations: DR, drug-resistant; IRIS, immune reconstitution inflammatory syndrome; TB, tuberculosis.
aTreatment completion criterion: The duration of prescribed DR-TB treatment will vary according to the study setting and may vary based on the drug-resistance profile and the clinical severity.
bClinical criterion: Resolution of all acute and chronic clinical manifestations (symptoms and physical signs) of TB disease, including both those that are constitutional and those that are specific to the affected anatomical
sites. Constitutional manifestations: TB can cause decreased activity level, decreased appetite, failure to thrive, fever, and night sweats. The resolution of failure to thrive should be objectively demonstrated by a weight gain
equal or greater than that required to follow the child’s baseline weight-for-age percentile (on the WHO Child Growth Chart [53–54]) over the treatment period. For consistency, we suggest use of the current (pretreatment)
percentile, because predisease measurements may not be available in all children. Manifestations specific to the affected anatomical site(s): TB has myriad manifestations given that necrotic lymph node infiltration into
contiguous structures and lymphohematogenous spread of Mycobacterium tuberculosis can lead to disease in virtually any tissue of the body. An exhaustive list of manifestations is therefore not possible. The following is a
list of examples of common tuberculous clinical syndromes, organized by organ systems: pulmonary/pleural (eg, pneumonia; pleural effusion); cardiovascular (eg, pericarditis; vasculitis); digestive (eg, enteritis; pancreatitis;
hepatitis); urinary (eg, nephritis); endocrine (eg, adrenal insufficiency; thyroiditis); hematologic (eg, anemia); lymphatic (eg, lymphadenitis; splenic abscess); nervous (eg, meningitis; parenchymal granuloma); musculoskeletal
(eg, arthritis; osteomyelitis); integumentary (eg, nodular skin disease); and reproductive (eg, salpingitis; tubo-ovarian mass; epididymitis). All manifestations of persisting disease activity should be resolved by the completion
of TB treatment. However, manifestations associated with sequelae (ie, secondary complications after healing of TB disease) such as permanent lung scarring (eg, bronchiectasis), neurological deficits (eg, cognitive
impairment; cranial nerve palsy), and joint/bone deformities (eg, gibbus) should be excluded from this criterion.
cRadiological criterion: Improvement of imaging abnormalities of all of the following: (a) lymph nodes (after effective DR-TB treatment, the enlarged lymph nodes of the majority of children will have normalized in size;
however, a small minority may have mildly enlarged lymph nodes or have developed calcifications); (b) lung parenchyma (after effective DR-TB treatment, the parenchymal lesions of the majority of children will have
resolved; however, a minority may only present improvement [reduction in size and/or intensity of lesions], or have developed calcifications or fibrotic lesions); and (c) pleural space (after effective DR-TB treatment, the
pleural lesions of the majority of children will have resolved; however, some may have residual pleural thickening or calcifications).
dMicrobiological criterion: In those children with bacteriologically confirmed disease, at least 3 consecutive negative mycobacterial cultures of respiratory specimens (eg, sputum; gastric aspirate/lavage) during the treatment
course, with at least 1 in the last 12 months of treatment, and no positive cultures during the minimum length of treatment after culture conversion.
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7some children with HIV infection who are started on anti-
retroviral therapy may experience a radiological deteriora-
tion despite clinical improvement due to immune
reconstitution inﬂammatory syndrome (IRIS) [47-49].
Nevertheless, this phenomenon is unlikely to inﬂuence
classiﬁcation of ﬁnal disease outcome, because IRIS typi-
cally presents early in the treatment course and resolves
before ﬁnal outcome is determined.
We propose that other treatment outcomes which
should be recorded are primary death and primary
default. The ﬁrst term would apply in a child who is diag-
nosed with DR-TB disease but dies before receiving
DR-TB treatment; the second term would apply in a child
who refuses treatment or is not given treatment or is lost to
follow-up before DR-TB treatment is initiated. Finally, for
the purpose of assigning classiﬁcation of ﬁnal disease
outcome, we propose that the outcome of treatment
failure be assigned if a child has had ongoing sputum
culture positivity or does not meet criteria for both clinical
and radiological improvement (Table 4), after more than 6
months of receiving an appropriate DR-TB treatment
regimen in the absence of IRIS. It should be noted that this
deﬁnition is intended for research use such as analyzing
outcomes in treatment cohorts, and it is not intended to
guide clinical decisions about individual patients. More re-
search is needed to identify the optimal durations of the in-
tensive and continuation phases for children with DR-TB,
as well as to identify optimal cutoffs for assigning ﬁnal
treatment outcomes speciﬁcally for children with DR-TB.
CONCLUSIONS
Currently, there is a concerning paucity of data regarding
childhood DR-TB and inconsistent use of classiﬁcations
for cases, treatment, and outcome. More pediatric studies
are urgently needed. Overall, the study of children with
DR-TB requires similar approaches to research in adults.
However, many existing adult tools require adaptation for
the speciﬁc requirements of studies of childhood DR-TB.
The standard deﬁnitions and terminology proposed here
will allow improvements in data collection for clinical re-
search and reporting of study ﬁndings, thereby facilitating
comparison across different settings and populations, as
well as promoting a stronger evidence base for policy-
makers and guideline development.
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